The impact of early acute rejection on kidney graft survival after repeat kidney transplantation

Introduction. Despite the improvements in immunosuppressive therapy, the growing number of repeat kidney transplantations and associated risks of acute rejection make it relevant to assess the impact of early acute rejection on a long-term kidney graft survival.
Objective. The aim of the study was to evaluate the rate, the clinical aspects of early acute rejection after repeat kidney transplantation and the outcomes of its treatment, to perform the assessment of the impact of rejection episodes on a long-term kidney graft survival.
Material and methods. We carried out the retrospective analysis of kidney graft survival after 121 repeat kidney transplantations performed in N.V. Sklifosovsky Research Institute for Emergency Medicine in the period from 2007 to 2018. Group I included 96 recipients after kidney transplantation without acute rejection in postoperative period. Group II consisted of 25 patients with early acute rejection after kidney transplantation. We performed the assessment of the impact of early acute rejection on the kidney graft survival in comparison with recipients with uncomplicated postoperative period. Statistical processing was carried out by nonparametric methods. Survival was assessed using the Kaplan–Meier curves.
Results. 1-year and 3-year kidney graft survival rates amounted to 90.3% (95%, confidence interval 85–95) and 85.4% (95%, CI 79–91), respectively, in recipients of Group I; and 72% (95%, CI 58–86) and 60% (95%, CI 46–76) in patients of Group II. Significant differences in 1-year and 3-year kidney graft survival between patients of Group I and II have been noticed (P=0.0022 and P=0.0065, respectively).
Conclusions. Patients with early acute rejection after kidney transplantation had poorer kidney graft survival in comparison with patients without rejection episodes in postoperative period.

1. Naik RH, Shawar SH. Renal Transplantation Rejection. In: StatPearls [Internet]. Treasure Island (FL): Stat- Pearls Publishing; 2020. PMID: 3197171 Available at: https://pubmed.ncbi.nlm.nih.gov/31971715/ [Accessed April 9, 2021].

2. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibodymediated rejection: current status and novel approaches. Am J Transplant. 2014;14(2):255–721. PMID: 24401076 https://doi.org/10.1111/ajt.12589

3. Halloran PF, Reeve JP, Pereira AB, Hidalgo LG, Famulski KS. Antibodymediated rejection, T cell-mediated rejection, and the injury-repair response: new insights from the Genome Canada studies of kidney transplant biopsies. Kidney Int. 2014;85(2):258–264. PMID: 23965521 https://doi.org/10.1038/ki.2013.300

4. Larpparisuth N, Vongwiwatana A, Vareesangthip K, Cheunsuchon B, Parichatikanon P, Premasathian N. Clinicopathologic features and treatment response of early acute antibody-mediated rejection in Thai kidney transplant recipients: a single-center experience. Transplant Proc. 2014;46(2):474–476. PMID: 24655992 https://doi.org/10.1016/j.transproceed.2013.12.022

5. Gubensek J, Buturovic-Ponikvar J, Kandus A, Arnol M, Lindic J, Kovac D, et al. Treatment of antibody-mediated rejection after kidney transplantation – 10 years' experience with apheresis at a single center. Ther Apher Dial. 2016;20(3):240–245. PMID: 27312908 https://doi.org/10.1111/1744-9987.12430

6. Rodríguez Cubillo B, Pérez Flores I, Calvo N, Pascual A, Cortés JA, Moreno MA, et al. Antibody-mediated acute vascular rejection of kidney allografts: fifteen-year follow-up. Transplant Proc. 2016;48(9):2917–2919. PMID: 27932107 https://doi.org/10.1016/j.transproceed.2016.09.015

7. Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T. Effect of rabbit antithymocyte globulin on acute and chronic active antibody-mediated rejection after kidney transplantation. Transplant Proc. 2019;51(8):2602–2605. PMID: 31324482 https://doi.org/10.1016/j.transproceed.2019.02.051

8. Clayton PA, McDonald SP, Russ GR, Chadban SJ. Long-term outcomes after acute rejection in kidney transplant recipients: an ANZDATA analysis. J Am Soc Nephrol. 2019;30(9):1697– 1707. PMID: 31308074 https://doi.org/10.1681/ASN.2018111101

9. Davis S, Cooper JE. Acute antibodymediated rejection in kidney transplant recipients. Transplant Rev (Orlando). 2017;31(1):47–54. PMID: 28126347 https://doi.org/10.1016/j.trre.2016.10.004

10. Solez K, Racusen LC. The Banff classification revisited. Kidney Int. 2013;83(2):201–206. PMID: 23235566 https://doi.org/10.1038/ki.2012.395

11. Roufosse C, Simmonds N, Groningen MC-van, Haas M, Henriksen KJ, Horsfield C, et al. A 2018 reference guide to the Banff classification of renal allograft pathology. Transplantation. 2018;102(11):1795–1814. PMID: 30028786 https://doi.org/10.1097/TP.0000000000002366

12. Banff foundation for allograft pathology. Available at: https://banfffoundation.org [Accessed April 9, 2021].

13. Morris PJ, Knechtle SJ. Kidney transplantation: principles and practice. 7th ed. Elsevier Science; 2013.

14. Comai G, Ravaioli M, Baraldi O, Cuna V, Gasperoni L, D''Arcangelo GL, et al. Treatment of Acute Antibody-Mediated Rejection. Contrib Nephrol. 2017;190:156-167. PMID: 28535527 https://doi.org/10.1159/000468962

15. Zhang R. Donor-specific antibodies in kidney transplant recipients. Clin J Am Soc Nephrol. 2018;13(1):182–192. PMID: 28446536 https://doi.org/10.2215/CJN.00700117

16. Cooper JE. Evaluation and treatment of acute rejection in kidney allografts. Clin J Am Soc Nephrol. 2020;15(3):430– 438. PMID: 32066593 https://doi.org/10.2215/CJN.11991019